About Takeda
Takeda news and updates
Takeda recognized as M&A Deal of the Year
Takeda Pharmaceutical Company Limited was named the M&A Deal of the Year.
Jan 1, 2019 | acuris.comCodebiotx partners with Takeda Pharmaceutical Co.
Code Biotherapeutics (PA, USA), a gene therapy company, has announced a strategic collaboration with Takeda (Tokyo, Japan), a patient-focused global pharmaceutical company.
Jan 1, 2022 | regmednet.comTakeda Pharmaceutical Co. hired Rute Fernandes as General Manager on Feb 8th 21'.
TORONTO, Feb. 8, 2021 /CNW/ - Takeda Canada Inc. (" Takeda Canada ") is pleased to announce the appointment of Rute Fernandes as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company.
Jan 1, 2021 | biospace.comTakeda Pharmaceutical Co. invests into Takeda Pharmaceutical Company Limited in $5.14M
In addition to the funding of the multi-target research collaboration, Takeda will invest €4.6 million in convertible debt through its venture arm, Takeda Ventures, Inc. (“TVI”), to support Egle’s corporate growth and internal programs on IL-2-based Treg modulation.
Jan 1, 2020 | businesswire.comTakeda Pharmaceutical Co. invested into Avidity Biosciences, Inc. in $30M on Jan 1st 12'.
Avidity has raised $30 million in venture financing from a top-tier group of investors, including Takeda Ventures, Alethea Capital, Alexandria Real Estate Equities, Brace Pharma, EcoR1 Capital, F-Prime Capital, Moore Venture Partners, and Boxer Capital of Tavistock Group.
Jan 1, 2019 | prnewswire.comSamsung Electronics Co. partners with Takeda Pharmaceutical Co.
Samsung, best known for its smartphones and television sets, is forming a partnership with Takeda Pharmaceutical Co. of Japan to jointly fund and develop multiple...
Jan 1, 2017 | wsj.comTakeda Pharmaceutical Co. launched OnePath Patient Support Program on Jul 7th 20'.
TORONTO, July 7, 2020 /CNW/ - As part of its on-going effort and commitment to provide care for Canadian patients, Takeda Canada Inc. is proud to introduce the new OnePath ® Patient Support Program.
Jan 1, 2020 | newswire.caTakeda Pharmaceutical Co. launched Takeda Canada Innovation Challenge on Jan 10th 22'.
TORONTO, Jan. 10, 2022 /CNW/ - Takeda Canada Inc. is pleased to announce the launch of the Takeda Canada Innovation Challenge, an initiative that aims to discover new and breakthrough digital technologies and artificial intelligence (AI) solutions that support enhanced patient care.
Jan 1, 2022 | newswire.caTakeda Pharmaceutical Co. launched CoVIg-19 Plasma Alliance on Jan 1st 20'.
At the beginning of the year, a large group of leading plasma companies, with CSL Behring and Takeda as founding members, launched the CoVIg-19 Plasma Alliance, with the aim of advancing the development and provision of a hyperimmune drug in the global fight against COVID-19.
Jan 1, 2020 | cslbehring.chTakeda Pharmaceutical Co. hires Serina Fischer as General Manager for India operations
Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, announced the appointment of Serina Fischer as its General Manager for India operations.
Jan 1, 2022 | hrnxt.comTakeda Pharmaceutical Co. launches Spot Lymphoma, Stop Lymphoma
Takeda Healthcare Philippines Inc. (Takeda Philippines) launched their “Spot Lymphoma, Stop Lymphoma” initiative to help in the government’s efforts towards a cancer-free Philippines.
Jan 1, 2022 | metrocebu.newsTakeda Pharmaceutical Co. acquired Colcrys on Apr 1st 12'.
For instance, in April 2012, Takeda Pharmaceutical (Japan-based) acquired the URL Pharma Inc., a Philadelphia-based company, in order to expand its gout disease treatment portfolio with the acquisition of marketed gout therapy Colcrys (colchicine), developed by URL Pharma Inc.
Jan 1, 2022 | medgadget.comTakeda Pharmaceutical Co. is developing DNL593
Denali entered a strategic collaboration with Takeda to jointly develop and commercialise DNL593, which is intended to slow or prevent FTD-GRN progression by increasing intracellular and extracellular functional PGRN levels.
Jan 1, 2022 | clinicaltrialsarena.comTakeda Pharmaceutical Co. partners with Infozoneus
To find a solution Takeda teamed up with Infozone Intelligence for guidance and to perform a UX audit to identify quick wins to improve their UI and increase usability.
Jan 1, 2022 | infozoneus.comVenkayya left Takeda Pharmaceutical Co. as chief executive officer on Feb 3rd 22'.
Venkayya, who stepped down as head of Takeda Pharmaceutical Co. ’s vaccines unit last month, is now the chief executive officer at Aerium Therapeutics, a biotech company backed by Omega Funds.
Jan 1, 2022 | bloomberg.comTakeda Pharmaceutical Co. launches Exkivity in the US
The NHS estimated that Takeda launched Exkivity in the US at a wholesale acquisition cost of $25,000 for a one-month supply of the oral pill.
Jan 1, 2022 | precisiononcologynews.comEngland partners with Takeda Pharmaceutical Co.
NHS England (NHSE) has entered into an agreement with drug manufacturer Takeda to make available a targeted new drug for a rare type of non-small-cell lung cancer.
Jan 1, 2022 | medscape.comTakeda Pharmaceutical Co. acquired Natpara for $62B on Mar 23rd 22'.
The company also explained separate manufacturing issues it’s addressing related to Natpara and said it’s taking a deeper look at the CRL: Takeda acquired Natpara when it bought out Shire for $62 billion in early 2019.
Jan 1, 2022 | endpts.comTakeda Pharmaceutical Co. is developing B cell therapies that cross the blood-brain barrier
Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders.
Jan 1, 2021 | medcitynews.comTakeda Pharmaceutical Co. is developing non-viral gene therapies for Hemophilia on Oct 1st 21'.
In October 2021, Poseida Therapeutics and Takeda started working together to develop non-viral gene therapies for Hemophilia and other genetic diseases.
Jan 1, 2022 | globenewswire.comTakeda Pharmaceutical Co. sold assets to Calithera Biosciences, Inc. in the amount of $45M on Mar 30th 21'.
Biopharmaceutical company Calithera Biosciences Inc. on Monday said was expanding its oncology pipeline as it agreed to acquire two clinical-stage compounds from Takeda Pharmaceutical Co. Ltd.
Jan 1, 2021 | marketwatch.comTakeda Pharmaceutical Co. partners with Amed
Takeda has teamed up with the Japan Agency for Medical Research and Development (AMED) through its Cyclic Innovation for Clinical Empowerment (CiCLE) program toward the development of a hypertrophic cardiomyopathy drug that uses induced pluripotent stem cell-derived cardiomyocytes with disease-causing mutations that were induced by gene-editing technology.
Jan 1, 2019 | genengnews.comTakeda Pharmaceutical Co. is developing Relugolix and MVT-602 on Jan 1st 16'.
In 2016, Myovant entered into an agreement with Takeda Pharmaceuticals International ( TAK ) for the exclusive, worldwide license, excluding Japan and other Asian countries, to develop Relugolix and MVT-602.
Jan 1, 2021 | seekingalpha.comTakeda Pharmaceutical Co. launched Phase 3 SHP643-301 study on Apr 12th 22'.
Takeda ( TSE:4502/NYSE:TAK ) today announced that the Phase 3 SHP643-301 study ( NCT04070326 ) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO ® (lanadelumab) in patients 2 to <12 years of age is complete and has met its objectives.
Jan 1, 2022 | neuro-central.comXula partners with Takeda Pharmaceutical Co.
Xavier University in New Orleans, the only historically Black and Catholic University in the U.S., has partnered with Takeda, a Japanese pharmaceutical company, in a multi-year effort to improve health equity for marginalized or disadvantaged populations.
Jan 1, 2022 | diverseeducation.comTakeda Pharmaceutical Co. recognized as top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards on Apr 4th 22'.
Takeda recently announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA).
Jan 1, 2022 | covnews.comTakeda Pharmaceutical Co. launches TAKHZYRO
Takeda ( TSE:4502/NYSE:TAK ) today announced TAKHZYRO ® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Jan 1, 2022 | yahoo.comFrazier Industrial Company partners with Takeda Pharmaceutical Co.
Three years after Frazier teamed up with Takeda to spin a gastrointestinal drug into a new startup named Phathom Pharmaceuticals, the biotech has delivered an approval.
Jan 1, 2022 | endpts.comTakeda Pharmaceutical Co. filed suit against Lupin Limited on Jul 1st 20'.
Arbor and Takeda sued Lupin in July 2020.
Jan 1, 2022 | bloomberglaw.comTakeda Pharmaceutical Co. launches HilleVax, Inc
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch HilleVax, Inc, a biopharmaceutical company, to develop and commercialize Takeda’s norovirus vaccine candidate.
Jan 1, 2021 | nckpharma.comTakeda Pharmaceutical Co. launches T-REX
Pharmaceutical company Takeda has announced a multi-year, multi-million-dollar initiative, called T-REX, that is aimed at furthering health equity in New Orleans.
Jan 1, 2022 | outsourcing-pharma.comTakeda Pharmaceutical Co. invested into assets : cell therapy facility in the amount of $38.4M in Grange Castle on Jan 1st 21'.
The opening follows an announcement in 2021 that Takeda would invest a further €36.4 million to support the expansion of the cell therapy facility at Grange Castle and create approximately 100 new jobs over the next three years.
Jan 1, 2022 | irishtechnews.ieTakeda Pharmaceutical Co. expanded facilities to Grange Castle on Jan 1st 21'.
Takeda will invest more than $36.4 million in its Grange Castle site to meet growing global demand.
Jan 1, 2021 | lscconnect.comTakeda Pharmaceutical Co. is developing COVID-19 vaccine on Apr 11th 22'.
Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc (NVAX.O), which was approved by Japanese regulators last month.
Jan 1, 2022 | kitco.comTakeda Pharmaceutical Co. launches Adynovate
Japanese drugmaker Takeda (TYO: 4502) has announced the Indian launch of Adynovate, an extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for hemophilia A patients.
Jan 1, 2022 | thepharmaletter.comTakeda Pharmaceutical Co. launches half-life recombinant Factor VIII treatment
Takeda Pharmaceutical Company Limited has launched an extended half-life recombinant Factor VIII (rFVIII) treatment under the brand name Adynovate using established technology (controlled PEGylation) for hemophilia A patients.
Jan 1, 2022 | financialexpress.comTakeda Pharmaceutical Co. expanded facilities to Ireland on Feb 1st 21'.
In February, Takeda announced a €36 million extension of its Grange Castle plant in Dublin, including the expansion of its cell therapy production line, the first such facility in Ireland.
Jan 1, 2021 | businessinsider.comTakeda Pharmaceutical Co. recognized as Best Workplaces™ List for 2022
Dubai, United Arab Emirates: Takeda, the R&D-driven global biopharmaceutical company, has been included among UAE’s Best Workplaces™ List for 2022.
Jan 1, 2022 | zawya.comTakeda Pharmaceutical Co. is developing wearable device that will track lifestyle habits
Takeda and Daiichi Sankyo have announced that they will work on a new research project, along with Tohoku University and MICIN, a digital health and telemedicine company, to develop a wearable device that will track lifestyle habits.
Jan 1, 2022 | pmlive.comTakeda Pharmaceutical Co. recognized as Great Place to Work
Takeda was also recognised as a Great Place to Work in the Middle East and follows numerous other accolades for its award-winning corporate culture, including certification as a Global Top Employer.
Jan 1, 2022 | biznesstransform.comTakeda Pharmaceutical Co. partnered with PeptiDream Inc. on Dec 1st 20'.
For instance, in December 2020, Takeda Pharmaceutical Co Ltd. announced a collaborative research and exclusive license agreement with Peptidream Inc.
Jan 1, 2021 | expertmarketresearch.comTakeda Pharmaceutical Co. partnered with Rarediseases on Jun 9th 22'.
In response to this Takeda, the R&D-driven global biopharmaceutical company, in Partnership with Rare Diseases South Africa, launched their ‘I am 15’ campaign to raise awareness for South Africans living with rare diseases.
Jan 1, 2022 | capetalk.co.zaTakeda Pharmaceutical Co. increases headcount by 40
Japanese pharmaceutical group Takeda will be expanding its production site in Pierre-à-Bot and build a new aseptic filling line, an investment of CHF 200 million with the creation of 40 new jobs.
Jan 1, 2022 | ggba-switzerland.chTakeda Pharmaceutical Co. expands facilities to Cambridge, United Kingdom
Japanese multinational pharmaceutical company Takeda agreed to lease an entire 16-story building planned by Blackstone's BioMed Realty in Boston's Kendall Square where the company said it plans to establish a central campus at the center of the region's life science hub in Cambridge.
Jan 1, 2022 | costar.comTakeda Pharmaceutical Co. expands offices in Kendall, Florida, United States
Takeda is also expanding its existing space in 650 E. Kendall to include two additional floors, making the company the sole laboratory and office tenant in the building.
Jan 1, 2022 | commercialsearch.comCheng leaves Takeda Pharmaceutical Co. as head of Global Value & Access for Cell Therapies, Pipeline and Business Development
Cheng, who joined AmerisourceBergen in April, comes from Takeda, where he most recently served as the head of Global Value & Access for Cell Therapies, Pipeline and Business Development.
Jan 1, 2022 | fiercepharma.comTakeda Pharmaceutical Co. hires Karen Correa as VP, head of global clinical operations
When Karen Correa joined Takeda as VP, head of global clinical operations, she made improved communications her top priority.
Jan 1, 2022 | lifescienceleader.comTakeda Pharmaceutical Co. partnered with BioMed Realty on Jun 22nd 22'.
Takeda ( TSE:4502/NYSE:TAK ) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square.
Jan 1, 2022 | businesswire.comTakeda Pharmaceutical Co. launches upgraded version of myPKFiT
Takeda Pharmaceutical has released the upgraded version of myPKFiT, a personalized treatment guide software for routine preventive therapy of hemophilia A patients.
Jan 1, 2022 | koreabiomed.comTakeda Pharmaceutical Co. acquired Takeda Oncology on Jan 1st 08'.
She also previously held positions with Bank of America, a financial services company, and Millennium Pharmaceuticals, a biopharmaceutical company that was acquired by Takeda Pharmaceuticals Co.
Jan 1, 2021 | globenewswire.comF-star Therapeutics Inc. partnered with Takeda Pharmaceutical Co. on Jul 20th 22'.
F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Takeda.
Jan 1, 2022 | f-star.comTakeda Pharmaceutical Co. has issues with severe congenital protein C deficiency
The government approved Takeda’s Human Protein C to prevent and treat venous thrombosis and purpura fulminans in patients with severe congenital protein C deficiency.
Jan 1, 2022 | koreabiomed.comEuropean Society for Organ Transplant will partner with Takeda Pharmaceutical Co. on Sep 27th 22'.
In partnership with Takeda, ESOT is pleased to host a session at the European Health Forum Gastein on Tuesday 27 September 2022.
Jan 1, 2022 | esot.orgTakeda Pharmaceutical Co. launches Cerevance
Takeda and venture capital firm Lightstone Ventures launched Cerevance with a $36 million Series A round.
Jan 1, 2022 | biopharmadive.comTakeda Pharmaceutical Co. launched rebate program for patients who discontinued treatment on Aug 9th 21'.
Last year, Takeda launched a rebate program for patients who discontinued treatment with lung cancer drug Alunbrig within three months.
Jan 1, 2022 | fiercepharma.comTakeda Pharmaceutical Co. expands facilities to Germany
In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine production facility in Singen, Germany, won in the Pharma 4.0 category.
Jan 1, 2022 | covnews.comTakeda Pharmaceutical Co. invests into assets : plant in the amount of $132M in Germany
Takeda is investing 130 million euros ($132 million) to build a plant in Germany that can make 50 million doses of its dengue vaccine a year.
Jan 1, 2022 | nikkei.comTakeda Pharmaceutical Co. invests into assets : 3,530-square-metre commercial cell therapy manufacturing facility in the amount of $84M in Lexington, Massachusetts, United States
Similarly, Japan-based R&D-driven biopharmaceutical manufacturer Takeda Pharmaceutical announced its plans to invest $84m to build a 3,530-square-metre commercial cell therapy manufacturing facility in Lexington, Massachusetts.
Aug 25, 2022 | investmentmonitor.aiTakeda Pharmaceutical Co. launched Takhzyro injection on Apr 1st 22'.
Read: In April, Japanese pharma giant Takeda ( TAK ), a market leader in HAE, launched its Takhzyro injection for the condition in the U.S.
Aug 22, 2022 | seekingalpha.comThomas Willemsen will leave Takeda Pharmaceutical Co. as CEO and president on Oct 1st 22'.
Willemsen joins Tessa from Takeda Pharmaceuticals, where he served as senior vice president, Asia Pacific, leading the transformation of Takeda across 10 markets and enhancing its focus on rare and genetic diseases, oncology, and vaccines.
Aug 26, 2022 | biospace.comTakeda Pharmaceutical Co. is developing microbiome-based medicines for inflammatory bowel disease on Aug 26th 21'.
Takeda has ended a long-running deal with Finch Therapeutics to develop microbiome-based medicines for inflammatory bowel disease, the latest in a string of setbacks the biotechnology company has suffered since going public last year.
Aug 26, 2022 | biopharmadive.comTakeda Pharmaceutical Co. will launch FIN-525 to pipeline on Sep 1st 24'.
Two years later, Takeda added FIN-525 to its pipeline, with Finch working on feasibility studies.
Sep 1, 2022 | fiercebiotech.comTakeda Pharmaceutical Co. recognized as 2022 Best Practitioner
Faye Zeidlhack, Global Travel Manager for BCD client Takeda, was named 2022 Best Practitioner by BTN Group.
Aug 29, 2022 | bcdtravel.comPrometheuslabs partnered with Takeda Pharmaceutical Co. on Sep 14th 22'.
Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients.
Sep 13, 2022 | prometheuslabs.comTakeda Pharmaceutical Co. is developing Antibody Targeted Amanitin Conjugate
Ladenburg, Germany, 9 September 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Takeda signed a license agreement granting Takeda an exclusive license to commercially develop an Antibody Targeted Amanitin Conjugate directed to a previously selected target molecule.
Sep 9, 2022 | marketscreener.comTakeda Pharmaceutical Co. launched CDPATHTM program on Aug 19th 22'.
Takeda recently announced the national launch of the CDPATHTM program, which includes an innovative, validated personalized prognostic tool that uses blood tests to help predict the potential risk of developing serious Crohn’s disease-related complications.
Sep 18, 2022 | medtechasia.inTakeda Pharmaceutical Co. expands facilities to Belgium
Takeda will pump €300 million ($299 million) into expanding its manufacturing site in Lessines, Belgium, a city around 30 miles southwest of Brussels.
Sep 14, 2022 | endpts.comTakeda Pharmaceutical Co. hires Molly Rabinovitz Stock as U.S. business unit storyteller
DEERFIELD, MA: Takeda has hired Molly Rabinovitz Stock as its U.S. business unit storyteller.
Sep 26, 2022 | prweek.comTakeda Pharmaceutical Co. is developing RNAi project
Arrowhead and its partner Takeda are developing an RNAi project designed to reduce the hepatic production of Z-AAT.
Sep 28, 2022 | evaluate.comTakeda Pharmaceutical Co. launches CDPath prognostic assay in the US
Takeda has launched its CDPath prognostic assay in the US aimed at helping Crohn's disease patients understand the severity of their diagnoses and make better decisions on how to manage symptoms and disease progression.
Sep 30, 2022 | genomeweb.comTakeda Pharmaceutical Co. promoted Julie Kim to president of the U.S. business unit on Oct 6th 22'.
Julie Kim was promoted to president of the U.S. business unit of Takeda Pharmaceutical Company Limited (Nasdaq: TAK) earlier this year after three years heading up the company's plasma-derived therapies division.
Oct 6, 2022 | bizjournals.comTakeda Pharmaceutical Co. is developing ZED1227/TAK-227 on Oct 20th 22'.
Takeda ( TSE:4502/NYSE:TAK ), Zedira and Dr. Falk Pharma GmbH today announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease.
Oct 20, 2022 | biospace.comTakeda Pharmaceutical Co. is developing transformative therapies for celiac disease on Oct 21st 22'.
“With three novel programs now in the clinic, Takeda is at the forefront of developing transformative therapies for celiac disease and is advancing multiple therapies for patients living with this challenging lifelong autoimmune condition.”
Oct 20, 2022 | cn-info.netPatientsLikeMe Inc partners with Takeda Pharmaceutical Co.
PatientsLikeMe has partnered with Takeda to better understand the holistic patient journey – including the care partner experience by gathering information about the transplant surgery and recovery, particularly if your loved one experienced CMV infection.
Oct 17, 2022 | mbsciences.comTakeda Pharmaceutical Co. partners with Falk Pharma Australia Pty
Japanese gastroenterology giant Takeda (TYO: 4502) has inked a deal with German firms Zedira and Dr Falk Pharma for the development of a celiac disease candidate, TAK-227.
Oct 19, 2022 | thepharmaletter.comTakeda Pharmaceutical Co. partnered with Dr. Falk Pharma GmbH on Oct 20th 22'.
(RTTNews) - Takeda Pharmaceutical Company Limited (TKPHF.PK) Thursday announced partnership with Zedira and Dr. Falk Pharma GmbH to develop ZED1227/TAK-227, a Phase 2b investigational therapy to treat of celiac disease.
Oct 19, 2022 | nasdaq.comTakeda Pharmaceutical Co. partners with Discovery Education
Takeda is adding another to the list, partnering with digital education platform Discovery Education to launch a health equity education project.
Nov 18, 2022 | prweek.comTakeda Pharmaceutical Co. acquired Iclusig for $5.2B on Jan 1st 17'.
Takeda acquired Iclusig as part of its $5.2 billion takeover of Ariad Pharma in 2017, part of a push into oncology by the Japanese pharma group under chief executive Christophe Weber.
Nov 18, 2022 | pharmaphorum.comNimbustx sells assets to Takeda Pharmaceutical Co.
(RTTNews) - Takeda (TAK) said it will acquire NDI-034858 from Nimbus Therapeutics.
Dec 13, 2022 | nasdaq.comTakeda Pharmaceutical Co. sold assets to Horizon Therapeutics plc in the amount of $115M on Feb 1st 20'.
Horizon purchased the three-building campus from Takeda Pharmaceuticals in February 2020 for $115M, relocating from Lake Forest, Patch reported.
Dec 13, 2022 | bisnow.comTakeda Pharmaceutical Co. launched innovative healthcare platform on Jan 1st 20'.
In 2020, for instance, Takeda Pharmaceuticals and Kanagawa Prefecture launched an innovative healthcare platform that integrates wearable-device monitoring with online medication guidance and drug delivery.
Dec 14, 2022 | mg.co.zaTakeda Pharmaceutical Co. acquires Nimbustx for $4B
Takeda will acquire Nimbus Therapeutics for $4 billion and gain rights to its allosteric TYK2 Inhibitor to address multiple immune-mediated diseases.
Dec 14, 2022 | europeanpharmaceuticalreview.comTakeda Pharmaceutical Co. launches digital gastroenterology portal for healthcare practitioners
Working together since 2017 across several projects and campaigns, Takeda and SGA previously launched a digital gastroenterology portal for healthcare practitioners, developed an IBD program for nurses further to patient educational videos, hosted an IBD Masterclass Congress, and launched MyInteract, a platform for Vedolizumab data.
Dec 19, 2022 | zawya.comTakeda Pharmaceutical Co. is developing vonoprazan in the West
Takeda granted Phathom Pharmaceuticals a license to develop vonoprazan in the West.
May 16, 2019 | bizjournals.comTakeda Pharmaceutical Co. launches Apple Watch app for tracking patients with depressive illnesses' daily mood, and cognition
For example, Takeda Pharmaceuticals and Cognition Kit introduced an Apple Watch app for tracking patients with depressive illnesses' daily mood, and cognition.
Nov 30, 2022 | reportsanddata.com